Meeting
2020 ASCO Virtual Scientific Program
Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function.
Authors
Katia Khoury
Georgetown Lombardi Cancer Center, Washington, DC
Katia Khoury , Ana Barac , Filipa Lynce , Xue Geng , Chau T. Dang , Anthony Francis Yu , Karen L. Smith , Christopher Gallagher , Paula Raffin Pohlmann , Raquel Nunes , Pia Maarit Herbolsheimer , Robert D. Warren , M. Barbara Srichai , Mark Hofmeyer , Federico M Asch , Ming Tony Tan , Claudine Isaacs , Sandra M. Swain
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Symptoms and Survivorship
Track
Symptom Science and Palliative Care
Sub Track
Late and Long-Term Adverse Effects
Clinical Trial Registration Number
NCT04143594
Citation
J Clin Oncol 38: 2020 (suppl; abstr 12069)
DOI
10.1200/JCO.2020.38.15_suppl.12069
Abstract #
12069
Poster Bd #
357
Abstract Disclosures
Funded by Conquer Cancer
Similar Posters
Poster
2023 ASCO Breakthrough
Retrospective observational study of outcomes in HER2-positive metastatic breast cancer patients treated with trastuzumab emtansine in single center.
First Author: WanChen Hsieh
First Author: Nicholas Patrick McAndrew
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC).
First Author: Adrienne Gropper Waks
Poster
2020 ASCO Virtual Scientific Program
One-year follow-up of health-related quality of life in the Swedish PREDIX HER 2 trial, evaluating docetaxel, trastuzumab sc, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2 positive breast cancer.
First Author: Yvonne Brandberg